Stryker's first bone tumor ablation system with
patented microinfusion technology offers a reliable solution for
people living with painful metastatic tumors
Mich., USA, Sept. 20,
2022 /PRNewswire/ -- Stryker (NYSE:SYK), one of the
world's leading medical technology companies, announced today that
its OptaBlate bone tumor ablation system (OptaBlate) received
510(k) clearance from the U.S. Food and Drug Administration. The
addition of the OptaBlate technology to Stryker's Interventional
Spine (IVS) portfolio expands on its core competencies in vertebral
augmentation and radiofrequency ablation and completes its
portfolio of treatment options for metastatic vertebral body
"Stryker's new bone tumor ablation (BTA)
system is a significant improvement on existing technology"
"Stryker's new bone tumor ablation (BTA) system is a significant
improvement on existing technology and builds on Stryker's IVS
portfolio," said Dr. Anthony Brown,
a Vascular and Interventional Radiologist at Radiology Imaging
Associates, CO. "There is no more deserving patient population for
our attention and intervention; OptaBlate will change lives."
As Stryker's first Interventional Oncology technology, OptaBlate
optimizes all aspects of the procedure—from set-up to ablation.
Featuring four probes and Stryker's unique and patented
microinfusion technology*, OptaBlate allows physicians to easily
customize their procedure and reduce ablation time by three
Specific key features of the system include:
- Treatment of two vertebral body levels at once using a
- Quicker, more consistent ablation1
- Microinfusion technology, which keeps the zone hydrated,
reducing impedance errors and preventing charring1
"Our commitment to our customers and understanding their needs
has never been stronger. The collaboration has helped us to develop
a more efficient bone tumor ablation system to address their unmet
needs," said Greg Siller, Vice
President and General Manager, Interventional Spine business,
Stryker. "OptaBlate will help our customers provide another
treatment option for those suffering from painful metastatic
cancer, and this is just the beginning."
Stryker's Interventional Spine business will introduce its
OptaBlate as part of its minimally invasive portfolio at the North
American Spine Society Annual Meeting, Oct.
12-15, in Chicago, IL.
For questions, please click here.
About Stryker's Interventional
We are working to advance interventional care from diagnosis to
delivery. For more information, visit strykerivs.com and
connect with us on LinkedIn, Twitter, VuMedi, and Vimeo.
Stryker is one of the world's leading medical technology
companies and, together with its customers, is driven to make
healthcare better. The company offers innovative products and
services in Medical and Surgical, Neurotechnology, Orthopaedics and
Spine that help improve patient and healthcare outcomes. Alongside
its customers around the world, Stryker impacts more than 100
million patients annually. More information is available at
Sr. Director, Marketing Communications
- Stryker data on file
* As of 9/14, OptaBlate features the only microinfuser on the
Dr. Anthony Brown is a paid
consultant of Stryker. His statements represent his own opinions
based on personal experience and are not necessarily those of
Stryker. Individual results may vary.
This document is intended solely for the use of healthcare
professionals. A surgeon must always rely on his or her own
professional clinical judgment when deciding whether to use a
particular product when treating a particular patient. We do not
dispense medical advice and recommend that surgeons be trained in
the use of any particular product before using it in surgery.
The information presented is intended to demonstrate Stryker's
products. A physician must always refer to the package insert,
product label and/or instructions for use, including the
instructions for cleaning and sterilization (if applicable), before
using any of Stryker's products. Products may not be available in
all markets because product availability is subject to the
regulatory and/or medical practices in individual markets. Please
contact your representative if you have questions about the
availability of Stryker's products in your area.
Stryker or its affiliated entities own, use, or have applied for
the following trademarks or service marks: OptaBlate and Stryker.
All other trademarks are trademarks of their respective owners or
The absence of a product, feature, or service name, or logo from
this list does not constitute a waiver of Stryker's trademark or
other intellectual property rights concerning that name or
View original content to download